Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Paola Finsinger"'
Autor:
Maria Paola Martelli, Nicola Di Renzo, Antonio Curti, Nicola Stefano Fracchiolla, Luca Maurillo, Morena Caira, Paola Finsinger, Giuliana Gualberti, Felicetto Ferrara, Attilio Olivieri
Publikováno v:
Leukemia Research Reports, Vol 21, Iss , Pp 100453- (2024)
Real-world data on treatment patterns and outcomes of patients with acute myeloid leukemia unfit for intensive chemotherapy are lacking before the advent of precision medicine in this setting.Herein, we present the Italian sub-analysis of the CURRENT
Externí odkaz:
https://doaj.org/article/9fa1436bfcfa4bcd96e907ac0f0822ca
Autor:
Massimo Breccia, Adriano Salaroli, Giuseppina Loglisci, Paola Finsinger, Alessandra Serrao, Giuliana Alimena
Publikováno v:
Haematologica, Vol 97, Iss 2 (2012)
Externí odkaz:
https://doaj.org/article/6a134ab9a19f4f3a97c1f0134dbe013c
Autor:
Massimo Breccia, Giuseppina Loglisci, Paola Finsinger, Adriano Salaroli, Alessandra Serrao, Giuliana Alimena
Publikováno v:
Haematologica, Vol 96, Iss 12 (2011)
Externí odkaz:
https://doaj.org/article/e65b35419def41eb945fce09be84c7ea
Autor:
Luca Laurenti, Lydia Scarfò, Anna Maria Frustaci, Alessandro Sanna, Emilia Iannella, Morena Caira, Paola Finsinger, Silvia Schifano, Benedetta Neri, Stefano Molica, Francesca Romana Mauro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab8da0586bbd8a2f248503117cd11934
https://hdl.handle.net/10807/232176
https://hdl.handle.net/10807/232176
Autor:
Morena Caira, Stefano Molica, Anna Maria Frustaci, Emilia Iannella, Gianluca Gaidano, Fabrizio Pane, Paola Finsinger, Luca Laurenti, Paolo Ghia, Marta Coscia, Paolo Sportoletti, Antonio Cuneo, Daniele Vallisa, Giuliana Gualberti, Francesca Romana Mauro
Publikováno v:
Blood
Introduction: All the available CLL therapies differ for relevant aspects as duration of response, mode of administration, treatment duration and adverse events: the CHOICE study was designed to investigate CLL patients' Quality of Life (QoL) and pre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::898ce391278e490e916866d84c1d2c3d
https://doi.org/10.1182/blood-2021-148308
https://doi.org/10.1182/blood-2021-148308
Autor:
Annalisa Chiarenza, Luciano Levato, Alessandro Gozzetti, Alessandra Tedeschi, Marika Porrazzo, Elisa Albi, Francesco Albano, Idanna Innocenti, Gianluigi Reda, Paola Finsinger, Livio Trentin, Simona Malgieri, Giuliana Gualberti
Publikováno v:
Blood. 138:4680-4680
Introduction Although plenty of data exists on efficacy and safety of CLL drugs, their impact on patients' Health-Related Quality of Life (HRQoL) is largely unknown (1-2). Documentation of drug safety via traditional use of adverse events (AE) in hem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aa6001489c7ef1439876afdab6d702c5
https://doi.org/10.1182/blood-2021-150274
https://doi.org/10.1182/blood-2021-150274
Autor:
Sara Grammatico, Roberto Foa, Alfonso Piciocchi, Marta Chisini, Maria Teresa Petrucci, Paola Finsinger
Publikováno v:
British Journal of Haematology. 172:554-560
This study aimed to review the clinical features and outcome of 53 patients with solitary plasmacytoma managed at our Institution between 1976 and 2012. Thirty-five patients had bone solitary plasmacytoma and 18 extramedullary solitary plasmacytoma.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0f708d464e4d97099876c4f083a5def
https://doi.org/10.1111/bjh.13870
https://doi.org/10.1111/bjh.13870
Autor:
Ida Carmosino, Roberto Latagliata, Michelina Santopietro, Paola Finsinger, Alessandra Serrao, Federico Vozella, Angela Romano, Adriano Salaroli, Chiara Montagna, Massimo Breccia, Giuliana Alimena, Irene Zacheo, Paola Volpicelli, Matteo Molica
Publikováno v:
American Journal of Hematology. 90:105-108
In patients with chronic myeloid leukemia (CML) responsive to imatinib, it is still unknown whether the long-lasting treatment could induce the appearance of a persistent/late chronic anemia. To highlight this issue, we revised 128 patients with CML
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1677fa4571186ca156c53502fa5fa0a1
https://doi.org/10.1002/ajh.23879
https://doi.org/10.1002/ajh.23879
Autor:
Ida Carmosino, Massimo Breccia, Paola Volpicelli, Chiara Montagna, Giuliana Alimena, Esther Oliva, Paola Finsinger, Angela Romano, Caterina Alati, Federico Vozella, Roberto Latagliata
Publikováno v:
Journal of Diabetes. 7:493-496
Background The aim of the present study was to assess the role of a concomitant type 2 diabetes as a potentially negative factor in the management of low-risk myelodysplastic syndrome (MDS) patients treated with high-dose (40 000 UI s.c. 2 times/week
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e16a83d4c647ff5ed0cb08d0030ed577
https://doi.org/10.1111/1753-0407.12203
https://doi.org/10.1111/1753-0407.12203
Autor:
Federico Vozella, Roberto Latagliata, Ida Carmosino, Paola Volpicelli, Chiara Montagna, Angela Romano, Amanda Roberto, Paola Finsinger, Marco Mancini, Massimo Breccia, Esther Oliva, Giuliana Alimena
Publikováno v:
Hematological Oncology. 33:48-51
Lenalidomide induces in patients with myelodysplastic syndrome (MDS) and del(5q) erythroid and cytogenetic response rates as high as 75% and 50%, respectively. It is still unclear, however, how long lenalidomide treatment should be continued and whet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0c4ccc414ce8fc17dfd09471d62b961a
https://doi.org/10.1002/hon.2134
https://doi.org/10.1002/hon.2134